quote:Originally posted by WineTrooper:
For any biotech people, SGEN and NKTR are ripe for long term holds. I know a guy who works in that space and he feels strongly that SGEN and NKTR are takeout ripened and could be doubles this year or next. Both have impressive products in circulation and some income along with good pipelines.
Yeah...PNWRF continue up
I agree that both these biotechs look like doubles from here.
I’m playing in some smaller names looking for multi-baggers (with higher risk obviously).